Latest Financial Results News

BLIS Technologies has kicked off FY27 with a 42% revenue increase and a return to EBITDA profitability, driven by strong B2B growth in Asia Pacific and China.

NZX Limited reported a robust first half of 2026 with operating earnings up 9.4% and net profit rising 18%. The exchange strengthened its funds management and wealth administration arms, relaunched equity derivatives, and declared a higher interim dividend. A new CEO is set to take the helm in September.

Auckland Airport posted a 3% revenue increase and a stable underlying profit of NZD 309 million in FY26, driven by robust passenger growth and a $1 billion infrastructure push, while cautioning on near-term fuel price volatility and geopolitical risks.

Shriro Holdings (ASX: SHM) posted a 7.5% revenue increase to $111 million for FY26, alongside a 44% jump in net profit after tax to $10.8 million. The company declared a fully franked final dividend and completed substantial share buy-backs, while guiding FY27 EBITDA to $12–15 million amid increased marketing spend.

Energy Fuels Inc. reported a transformative 2024 with a major acquisition boosting its heavy mineral sands assets, a uranium production ramp-up at key US mines, and commercial rare earth oxide output from its White Mesa Mill.

InvestSMART Group Limited swung to a net loss of $575,633 in FY26, marking a sharp reversal from the prior year’s profit, amid a strategic pivot including a pending $16 million sale of its Intelligent Investor business.

Australis Oil & Gas Ltd posted a $2.6 million net loss for 1H 2026 amid sharply reduced production volumes but is progressing its Tuscaloosa Marine Shale development with a key partner and a planned Q4 well spud.

Ironbark Balanced Income Limited reported a 5.6% decline in net profit to $2.89 million for FY2026, while its investment portfolio delivered a solid 7.8% return, outperforming its benchmark and maintaining fully franked dividends.

Percheron Therapeutics reduced its FY2026 loss to $4.79 million as it prepares to launch a pivotal phase II trial for its immuno-oncology drug HMBD-002, while managing a CEO transition and tightening cash reserves.

Artrya Limited marked its first full year of US commercial operations with a $25.18 million loss, driven by regulatory clearances, customer contracts, and an $80 million capital raise.

Ventia Services Group has won two major Intelligent Transport Systems maintenance contracts in Victoria's Central and East regions, valued at $160 million over five years, reinforcing its transport infrastructure foothold.

Solvar Limited posted a 6.2% decline in statutory net profit for FY26 to $29.5 million, while normalised earnings rose 7.5%. The lender declared a 19.5 cents fully franked dividend and expanded its Australian loan book by 10.5%, driven by growth in commercial lending.